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Frailty Measures of Patient-reported Activity and Fatigue
May Predict 1-year Outcomes in Ambulatory Advanced Heart
Failure: A Report From the REVIVAL Registry
ANURADHA LALA,1,2* PALAK SHAH,3,* SHOKOUFEH KHALATBARI,4 MATHEOS YOSEF,4 MARIA M. MOUNTIS,5
SHAWN W. ROBINSON,6 DAVID E. LANFEAR,7 JERRY D. ESTEP,5 NEAL JEFFRIES,8 WENDY C. TADDEI-PETERS,8
LYNNE W. STEVENSON,9 BLAIR RICHARDS,4 DOUGLAS L. MANN,10 DONNA M. MANCINI,1,2 GARRICK C. STEWART,11 AND
KEITH D. AARONSON12
New York, New York; Falls Church, Virginia; Ann Arbor, and Detroit, Michigan; Cleveland, Ohio; Baltimore, and Bethesda, Maryland;
Nashville, Tennessee; St. Louis, Missouri; and Boston, Massachusetts

ABSTRACT
Background: The Fried Frailty Phenotype predicts adverse outcomes in geriatric populations,
but has not been well-studied in advanced heart failure (HF). The Registry Evaluation of Vital
Information for Ventricular Assist Devices (VADs) in Ambulatory Life (REVIVAL) study prospectively collected frailty measures in patients with advanced HF to determine relevant assessments and their impact on clinical outcomes.
Methods and Results: HF-Fried Frailty was deﬁned by 5 baseline components (1 point each):
(1) weakness: hand grip strength less than 25% of body weight; (2) slowness based on time to
walk 15 feet; (3) weight loss of more than 10 lbs in the past year; (4) inactivity; and (5) exhaustion, both assessed by the Kansas City Cardiomyopathy Questionnaire. A score of 0 or 1 was
deemed nonfrail, 2 prefrail, and 3 or greater was considered frail. The primary composite outcome was durable mechanical circulatory support implantation, cardiac transplant or death at
1 year. Event-free survival for each group was determined by the Kaplan Meier method and
the hazard of prefrailty and frailty were compared with nonfrailty with proportional hazards
modeling. Among 345 patients with all 5 frailty domains assessed, frailty was present in 17%,
prefrailty in 40%, and 43% were nonfrail, with 67% (n = 232) meeting the criteria based on
inactivity and 54% (n = 186) for exhaustion. Frail patients had an increased risk of the primary
composite outcome (unadjusted hazard ratio [HR] 2.82, 95% conﬁdence interval [CI]
1.52 5.24; adjusted HR 3.41, 95% CI 1.79 6.52), as did prefrail patients (unadjusted HR 1.97,
95% CI 1.14 3.41; adjusted HR 2.11, 95% CI 1.21 3.66) compared with nonfrail patients, however, the predictive value of HF-Fried Frailty criteria was modest (Harrel’s C-statistic of 0.603,
P = .004).
Conclusions: The HF-Fried Frailty criteria had only modest predictive power in identifying
ambulatory patients with advanced HF at high risk for durable mechanical circulatory support,
transplant, or death within 1 year, driven primarily by assessments of inactivity and exhaustion. Focus on these patient-reported measures may better inform clinical trajectories in this
population. (J Cardiac Fail 2021;00:1 10)
Key Words: Heart failure, frailty, left ventricular assist device, heart transplant, outcomes.
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Frailty is deﬁned as a decreased physiological
reserve that renders patients vulnerable to stress
and is assessed by a variety of measures. Among
patients with heart failure (HF), the prevalence of
frailty has been reported across a broad range from
25% to 78% based on the patient population being
assessed and measures used .1,2 HF and frailty share
common symptoms that can be attributed to either
condition (eg, fatigue, exhaustion, weight loss).3 As
such, distinguishing the aspects of the frailty syndrome that are reversible with a therapeutic intervention for HF (eg, mechanical circulatory support
[MCS] or cardiac transplantation) vs those that are
independent, is critical.4
Several frailty indices have been proposed, some
of which are center or study speciﬁc,5 or focus on
select measures/maneuvers such as the hand grip
strength test6 and gait time,7 or are extrapolated
from quality of life questionnaires such as the ShortForm 12.8 The most commonly used frailty measure
is the Fried Frailty Phenotype (FFP), which deﬁnes
frailty by measures of weakness, slowness, inactivity,
exhaustion, and shrinking,9 likely owing to its ease
of assessment and generalizability. There are limitations to the FFP, however, that are important to consider with respect to its application in an advanced
HF population: (1) the measure was developed in an
ambulatory geriatric patient population with a low
prevalence of HF; (2) weight ﬂuctuations owing to
ﬂuid retention are common in patients with HF and
may mask unintended weight loss; and (3) the questionnaire used to assess patient inactivity is the Minnesota Leisure Time Activity scale, which is likely
irrelevant to patients with advanced HF, who rarely
participate in activities such as jogging or bowling.10
Thus, although the FFP is the most widely used
measure of frailty, it remains to be validated in the
setting of advanced HF owing to inconsistent application and criteria used in existing publications.
The Registry Evaluation of Vital Information for
VADs in Ambulatory Life (REVIVAL) prospectively
collected frailty measures in ambulatory patients
with advanced HF (Interagency Registry for
Mechanically Assisted Circulatory Support [INTERMACS] 4 7) to determine the relevant components
of frailty to this population and their individual as
well as collective impact on clinical outcomes. As
such, this registry offers the unique opportunity to
determine how measurements of frailty correlate
with worsening severity of HF requiring advanced
therapies. Using the rigor of a prospective, multicenter clinical study, we hypothesized that HF-speciﬁc modiﬁed FFP criteria (HF Fried Frailty) when
applied to ambulatory patients with advanced HF,
would be strongly associated with the 1-year composite outcome of durable MCS, cardiac transplantation, or death.

Methods
Data Source

The REVIVAL study was a prospective, observational cohort study of patients with ambulatory systolic HF recruited from 21 United States heart
transplant/MCS centers; enrollment occurred
between July 2015 and June 2016. Patients were eligible for enrollment if they had persistent New York
Heart Association functional classes II IV symptoms
despite optimal medical therapy as well as an additional high-risk feature such as a recent nonelective
HF hospitalization, heart transplant listing, objective
functional limitation, or evidence of neurohormonal
activation. Patients were excluded if they had a signiﬁcant noncardiac condition that would limit functional capacity or expected survival to less than
2 years, intravenous inotrope use, or chronic kidney
disease with a creatinine of 3.0 mg/dL or greater, or
were on dialysis. Detailed entry criteria and study
design have previously been published.11 Patient
demographic characteristics including age, sex, race,
and current HF status, including INTERMACS proﬁle,
were captured at the time of enrollment. During
this visit, a 6-minute-walk test was performed, handgrip strength was assessed, and quality of life questionnaires were completed. An independent
observational study monitoring board oversaw the
conduct of the REVIVAL study. The institutional
review board at each center and at the Data Coordinating Center at the University of Michigan
approved the study. All subjects provided written
informed consent before study participation.
The HF Fried Frailty Criteria

HF Fried Frailty was deﬁned by 5 components: (1)
weakness, (2) slowness, (3) weight loss, (4) inactivity, and (5) exhaustion. For weakness, the handgrip
strength was performed using a Jamar dynamometer. Peak grip strength was measured 3 times in the
dominant and nondominant hand. The average of
all measures was indexed to body weight, and less
than 25% of body weight was considered as meeting criterion for weakness.6 To assess for slowness
based on the 15-feet walk time, 7 seconds or more
was considered to meet the criterion for men 5’8”
or shorter and 6 seconds or more for men taller
than 5’8”. For women 5’3” or shorter, 7 seconds or
more met the threshold for slowness, and for
women taller 5’3”, 6 or more seconds qualiﬁed.9
An unintentional pound weight loss or 10 lbs or
more was considered meeting the criterion for
weight loss, collected at baseline visit from prior visits or by report. For inactivity, answers of extremely
limited or quite a bit limited on the Kansas City Cardiomyopathy Questionnaire (KCCQ) for any of the 5
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activity questions (including dressing oneself, showering/bathing, walking 1 block on level ground,
doing yardwork/housework/carrying groceries, and
climbing 1 ﬂight of stairs without stopping) were
considered to represent inactivity. The question on
hurrying or jogging was excluded given the
advanced nature of disease in this population.
Finally, an answer of extremely limited to moderately limited for either fatigue question was considered to constitute exhaustion10 (Appendix). For
each frailty domain in which the frailty criterion
was met, patients received 1 point. These were
summed and the total score was used to form the
following categories: nonfrail (0 1 points), prefrail
(2 points), or frail (3 points) (Central Illustration).
Outcomes

The primary end point of interest was the 1-year
composite outcome of durable MCS, transplant (as
a United Network for Organ Sharing previous status 1A or 1B), or death from any cause. Of note,
because MCS and transplantation were components
of the primary composite outcome, death following
either of these procedures was not assessed.
Although the REVIVAL registry followed patients
for 2 years, the 1-year end point was selected as a
time period during which the impact of baseline
frailty could exert its effect in the context of other
baseline characteristics.
Statistical Analysis

Categorical data were presented as number (%)
and continuous data were reported as mean § standard deviation or median [interquartile range].
Patient baseline characteristics were compared
between the three frailty classiﬁcation groups using
Pearson’s x2 or the Kruskal Wallis tests for categorical and continuous variables, respectively. Eventfree survival for each frailty group was determined
by the Kaplan Meier method and the risks of prefrailty and frailty compared with nonfrailty were
determined with proportional hazards modeling.
With regard to identifying which of the 5 modiﬁed FFP components are needed to optimize risk
prediction for the primary composite outcome, each
component was considered individually in a univariable analysis followed by multivariable analysis. All
variables in the univariable analyses were entered
into a backward elimination multivariable analysis.
The multivariable model was further adjusted for
body mass index because it was thought that
exhaustion, inactivity, and slow gait time may be
more commonly present in obese patients. The
KCCQ overall summary score and clinical summary
score were also assessed for association with the
composite outcome, as were the individual

components of the KCCQ to evaluate whether there
was an incremental predictive value of the HF-Fried
Frailty criteria over KCCQ. Further, contributions of
the inactivity and exhaustion domains of the KCCQ
were compared with the overall predictive value of
the KCCQ. To assess potential biased resulting from
missing components of HF-Fried data, Fisher’s exact
and 2-sample Wilcoxon rank-sum tests were used
to compare selected categorical and continuous
patient characteristics between the groups with
missing and nonmissing FFP data.
Results
Baseline Characteristics

Of the 400 enrolled patients, 345 patients had
assessments for all 5 frailty components at baseline.
Among this advanced HF cohort, the mean age was
60 years, 75% were men, more than two-thirds
were INTERMACS proﬁle 6 or 7, and nearly 60%
had a history of chronic kidney disease. The mean
left ventricular ejection fraction was 20% and the
mean 6-minute-walk test distance was 336 m
(Table 1). The characteristics of the patients for
whom all 5 components of the HF-Fried Frailty
index were not available (n = 55) were not signiﬁcantly different from the remainder of the study
sample with the exception of a higher proportion
of African American patients, and higher blood
urea nitrogen and international normalized ratio
(Supplemental Table 1).
With respect to the individual components of the
HF Fried Frailty index, 232 patients (67%) met the
criteria for inactivity and 186 (54%) met the criteria
for exhaustion. More than one-quarter of the sample (n = 89 [26%]) met the criteria for weakness by
handgrip strength, whereas only 28 (8%) patients
had a slow gait time and a negligible proportion of
patients reported a weight loss or more than 10 lbs
(3 patients [0.9%]). Based on these assessments, 149
patients (43%) were classiﬁed as nonfrail with 0 1
points, 139 patients (40%) were classiﬁed as prefrail
with 2 points, and 57 patients (17%) were classiﬁed
as frail with 3 or more points (Table 2).
There were no differences in age between the 3
groups; however, 50% of the frail group were
women compared with approximately 20% in the
prefrail and nonfrail cohorts (P < .001). Body mass
index was noted to higher in the frail patients than
in the nonfrail patients (32.7 § 6.8 vs 29.1 § 5.7,
P = .001). Importantly, patients with the most severe
HF (INTERMACS proﬁle 4) constituted a larger percentage of the frail group than of the prefrail or
nonfrail groups (14% vs 8.6% vs 6%, respectively;
P = .001) and New York Heart Association functional
class tracked similarly. Functional capacity was also
correspondingly more impaired in the frail group as
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Table 1. Baseline Characteristics Based on Frailty Classiﬁcation
Characteristic
Age (years)
Male sex
Race
African American/Black
American Indian/Alaskan Native
Asian
More than one race
Other/none of the above
Unknown/undisclosed
White
Hispanic/Latino
BMI, kg/m2
New York Heart Association functional class
I
II
III
IV
INTERMACS proﬁle
4
5
6
7
Hypertension
Diabetes (n = 344)
Chronic kidney disease
Peripheral vascular disease
COPD
History of stroke or TIA?
Atrial ﬁbrillation
Creatinine, mg/dL
BUN, mg/dL
AST, U/L
Albumin, g/L
INR (n = 335)
Hemoglobin, g/dL
Left ventricular ejection fraction (%)
ECG: LV dimension (d)
6-Minute walk distance (m)
Systolic blood pressure, mm Hg
Heart rate, bpm
Beta-blocker
ACE inhibitor
ARB
ARNI
ACE inhibitor/ARB/ARNI
Hydralazine
Nitrates
Mineralocorticoid receptor antagonist (spiro/eplerenone)
Loop diuretic

(1) Not frail
(n = 149)

(2) Prefrail
(n = 139)

(3) Frail
(n = 57)

Total
(n = 345)

62 [53 68]
120 (80.5)

62 [54 69]
110 (79.1)

61 [56 67]
28 (49.1)

62 [54 68]
258 (74.8)

34 (22.8)
0 (0.0)
3 (2.0)
1 (0.7)
2 (1.3)
1 (0.7)
108 (72.5)
9 (6.1)
28.4 [24.9 32.5]

24 (17.3)
0 (0.0)
4 (2.9)
3 (2.2)
4 (2.9)
1 (0.7)
103 (74.1)
11 (8.3)
29.3 [25.4 34.5]

18 (31.6)
1 (1.8)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
38 (66.7)
4 (7.1)
32.7 [27.5 37.1]

76 (22.0)
1 (0.3)
7 (2.0)
4 (1.2)
6 (1.7)
2 (0.6)
249 (72.2)
24 (7.1)
29.2 [25.4 34]

5 (3.4)
54 (36.2)
89 (59.7)
1 (0.7)

1 (0.7)
32 (23.0)
102 (73.4)
4 (2.9)

0 (0.0)
9 (15.8)
44 (77.2)
4 (7.0)

6 (1.7)
95 (27.5)
235 (68.1)
9 (2.6)

9 (6.0)
18 (12.1)
58 (38.9)
64 (43.0)
8 (5.4)
55 (36.9)
88 (59.1)
4 (2.7)
20 (13.4)
12 (8.1)
17 (11.4)
1.30 [1.09 1.60]
23 [18 34]
25 [21 31.5]
4.2 [3.9 4.45]
1.2 [1.1 1.9]
13.4 [12.5 14.6]
20 [15 25]
68 [62.05 75.20]
364 [326 439]
108 [98 120]
72 [65 84]
141 (94.6)
67 (45.0)
43 (28.9)
19 (12.8)
129 (86.6)
27 (18.1)
35 (23.5)
120 (80.5)

12 (8.6)
42 (30.2)
50 (36.0)
35 (25.2)
4 (2.9)
49 (35.3)
79 (56.8)
7 (5.1)
20 (14.4)
18 (13.0)
10 (7.2)
1.30 [1.01 1.63]
24 [18 35]
24 [19 32]
4.2 [3.9 4.4]
1.2 [1 2]
13.7 [12.4 14.7]
20 [17 25]
65.65 [61.60 73.05]
335 [270 384]
106 [98 114]
76 [65 84]
136 (97.8)
62 (44.6)
30 (21.6)
24 (17.3)
116 (83.5)
19 (13.7)
32 (23.0)
97 (69.8)

8 (14.0)
10 (17.5)
27 (47.4)
12 (21.1)
3 (5.5)
25 (44.6)
39 (68.4)
2 (3.6)
3 (5.3)
8 (14.0)
7 (12.3)
1.27 [1.06 1.67]
26 [19 37]
23 [18 29]
4.1 [3.9 4.4]
1.2 [1 2]
13.1 [12.3 14.2]
22 [18 30]
64.80 [57.85 70.60]
273 [183 335]
109 [97.5 117]
72.5 [66 82.5]
52 (91.2)
26 (45.6)
9 (15.8)
12 (21.1)
47 (82.5)
9 (15.8)
15 (26.3)
43 (75.4)

29 (8.4)
70 (20.3)
135 (39.1)
111 (32.2)
15 (4.4)
129 (37.5)
206 (59.7)
13 (3.8)
43 (12.5)
38 (11.0)
34 (9.9)
1.30 [1.05 1.61]
24 [18 36]
24 [20 32]
4.2 [3.9 4.4]
1.2 [1 2]
13.4 [12.4 14.5]
20 [15 25]
66.50 [61.05 73.85]
341 [280 402]
107 [98 117]
74 [65 84]
329 (95.4)
155 (44.9)
82 (23.8)
55 (15.9)
292 (84.6)
55 (15.9)
82 (23.8)
260 (75.4)

138 (92.6)

125 (89.9)

53 (93.0)

316 (91.6)

P value
.92
<.01
.21

.78
<.01
<.01

<.01

.54
.46
.32
.57
.19
.30
.39
.84
.68
.16
.60
.98
.19
.10
.04
<.01
.76
.71
.12
.99
.11
.30
.67
.59
.88
.11
.65

Nonfrail, prefrail, and frail deﬁned as a Fried Frailty Phenotype score of 0 1, 2, and 3 5, respectively.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; INR, international normalized ratio; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LV, left
ventricular; TIA, transient ischemic attack.
*Categorical data presented as number (%), continuous data presented as median [interquartile range].

Table 2. The Proportion of Patients With Each Component of Frailty
Frailty Component

Total Cohort (N = 345)

Nonfrail (n = 149 [43%])

Prefrail (n = 139 [40%])

Frail (n = 57 [17%])

Inactivity
Exhaustion
Weak hand grip strength
Slow gait time
Weight loss

232 (67.3)
186 (53.9)
89 (25.8)
28 (8.1)
3 (0.9)

50 (33.6)
17 (11.4)
14 (9.4)
2 (1.3)
0

127 (91.4)
115 (82.7)
26 (18.7)
9 (6.5)
1 (0.7)

55 (96.5)
54 (94.7)
49 (86.0)
17 (29.8)
2 (3.5)

Values are number (%).
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assessed by the 6-minute-walk test distance (262 §
106 m vs 325 § 92 m in the prefrail group and 375 §
85 m in the nonfrail group (P < .001)).
Relationship to Outcome

At 1 year, 75 patients (22% of the entire cohort)
experienced the primary composite outcome of
durable MCS (n = 41/75 [55% of composite]), urgent
cardiac transplant (n = 10/75 [13% of composite]), or
death (n = 24/75 [32% of composite]) and 14
patients were lost to follow-up. Patients categorized
as nonfrail had the greatest probability of survival
free of the primary composite end point (86.6%),
followed by patients classiﬁed as prefrail (73.8%);
patients deemed frail had the lowest probability
(64.9%, P = 0.003) (Figure 1). Durable MCS implantation was the most frequent outcome of the composite and occurred most frequently in the frail group
followed by the prefrail and ﬁnally nonfrail group
(19% vs 15% vs 6%, respectively) (Table 3).
Univariable and Multivariable Association of Frailty and
Primary End Point

The difference in hazards of the primary composite end point was signiﬁcantly different between
the frail and nonfrail groups (unadjusted hazard
ratio [HR] 2.82, 95% conﬁdence interval [CI]
1.52 5.24, P = .001; adjusted HR 3.41, 95% CI
1.79 6.52, P < .001), as well as between the prefrail
and nonfrail group (unadjusted HR 1.97, 95% CI
1.14 3.41, P = .016; adjusted HR 2.11, 95% CI
1.21 3.66, P = .008). There was, however, no signiﬁcant increased hazard in the frail vs prefrail group
(unadjusted HR 1.44, 95%CI 0.83 2.49, P = .198)
(Table 4). INTERMACS proﬁle was associated with
the primary composite outcome (proﬁles 4 and 5 vs
7 had a higher risk of durable MCS, transplantation,
or death than proﬁle 7 on univariable analysis) but
age, sex, and body mass index were not. Last, a
higher left ventricular ejection fraction was expectedly protective against the primary end point (HR
0.96, 95% CI 0.93 0.99 per 1% increase).
The overall Harrell's c-statistic of the HF-Fried
Frailty index in predicting the composite outcome
was 0.60. When considering the value of the individual components of the HF-Fried Frailty index, questions on inactivity and exhaustion drove predictive
power. The Harrell's c-statistic for inactivity was
c = 0.58 (HR 2.44, 95% CI 1.34 4.44, P = .035), and
for exhaustion c = 0.62 (HR 2.81, 95% CI 1.67 4.72,
P = .0001) (Table 5). Including both inactivity and
exhaustion, the c-statistic improved to 0.64, (95% CI
0.578 0.69). Even though KCCQ questions on inactivity and exhaustion constitute just 2 of many components of the Clinical and Overall Summary Scores,
the multivariable Cox model including just the

KCCQ inactivity and exhaustion components had
similar predictive ability to the KCCQ Clinical Summary Score: c = 0.64 (HR 0.98, 95% CI 0.97 0.99, P <
.0001); and the Overall Summary Score: c = 0.63 (HR
0.98, 95% CI 0.97 0.99, P < .0001) (Table 5).
Discussion
We used data from a prospective multicenter registry to assess the predictive value of 5 HF-speciﬁc
frailty measures, called the HF-Fried Frailty criteria,
among ambulatory patients with advanced HF to
report several meaningful ﬁndings. First, more than
one-half of the patients were classiﬁed as prefrail or
frail. Second, exhaustion and inactivity were the
most common frailty components observed. Third,
markers of frailty using a 5-component HF-Fried
Frailty index, tracked with ambulatory INTERMACS
proﬁles 4 7, with sicker patients being more frail.
Finally, prefrailty or frailty was associated with a 2to 3-fold risk of death or needing advanced therapies at 1 year, driven by patient reports of inactivity
and fatigue severity. The predictive value was modest, however, suggesting these frailty assessments,
originally appreciated in an elderly population, may
be less relevant in this younger cohort.
Assessment of Frailty in Advanced HF

Frailty is a syndrome characterized by an accumulation of deﬁcits, resulting in a depleted physiological reserve and limited ability to overcome
stressors.12 Its detection can be elusive; the syndrome relies on the characterization of symptoms
shared by both advanced HF and biological aging,3
and certain components (eg, inactivity and exhaustion) are not precisely measurable. The original
Fried construct used the Minnesota Leisure Time
Activities Questionnaire to assess inactivity wherein
activities such as running, dancing, and tennis, are
often beyond the physical abilities of patients with
advanced HF. 10,13 Although prior HF frailty publications have assessed inactivity and exhaustion using
a variety of techniques,14 we chose to use domains
of the extensively validated KCCQ.10 The KCCQ
inactivity and extent of exhaustion questions are
more relevant to HF and include challenges (if any)
in dressing, showering, and light housework as well
as frequency of fatigue with regular activities. The
advanced nature of disease in the REVIVAL cohort
is evidenced by high overall event rates compared
with other contemporary clinical trials in HFrEF. For
example, in REVIVAL 22% of patients had the composite end point at 1 year compared with 22% in
PARADIGM-HF15 at 27 months or 19% in EMPERORREDUCED16 at 16 months. Importantly, in REVIVAL,
HF hospitalizations were not included in the primary composite end point of left ventricular assist
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Figure 1. Survival free of primary composite end point.

device implantation, transplantation, or death. If
cardiovascular mortality and HF hospitalizations
were assessed, 36% of REVIVAL patients experienced this composite at 12 months and 48% by
24 months.

Prevalence of Frailty

Frailty measures are increasingly assessed to
reﬂect biologic age rather than chronologic age in
efforts to better prognosticate outcomes in patients
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Table 3. Clinical Outcomes at 1 Year by Frailty Category
Clinical Outcome

Nonfrail
(n = 149)

Prefrail
(n = 139)

Frail
(n = 57)

Primary composite end point
Durable MCS implantation
Urgent cardiac transplant
Death

20 (13.4)
9 (6.0)
1 (0.7)
10 (6.7)

35 (25.2)
21 (15.1)
6 (4.3)
8 (5.8)

20 (35.1)
11 (19.3)
3 (5.3)
6 (10.5)

Values are number (%). MCS, mechanical circulatory support.

with advanced HF. Yet the absence of a HF-speciﬁc
frailty tool has been a signiﬁcant limitation.12 The
FFP is used to predict outcomes, particularly in
elderly patients and in the surgical settings9; thus, its
applicability to predict clinical trajectories among
patients with ambulatory advanced HF is of interest.
The HF-Fried Frailty criteria used in this study
included HF-speciﬁc assessments of weight loss,
hand grip strength, gait time, inactivity, and exhaustion. Using this deﬁnition, 57% of patients with
advanced HF were considered prefrail or frail, with
40% classiﬁed as prefrail with 2 domains positive
(with >80% owing to inactivity and exhaustion) and
less than one-ﬁfth of patients (17%) classiﬁed as
frail with 3 or more domains positive. Poor handgrip
strength was the most common qualifying assessment after inactivity and exhaustion.
Clinical Characteristics of Patients With HF With Frailty

Frailty has typically been considered a comorbid
condition of the elderly. In scenarios of advanced
end-organ disease, however, the recognition of
frailty is important regardless of biological age, with
a similar age distribution for frail and non-frail
patients among patients referred for heart transplantation.17 The present cohort is relatively young,
so measures outside the Fried construct may be
more meaningful. Although more women were frail
than men (consistent with prior frailty publications

Table 5. Discriminatory Power of the Components of the
Heart Failure Fried Frailty Toward the Primary Composite
End Point
Frailty
Characteristic

Harrel’s CStatistic

Hazard Ratio
[95% CI]

Weak handgrip
strength
Slow gait time
Inactivity
Exhaustion
Overall HF-FF
Prefrail
Frail
Modiﬁed KCCQ
Inactivity
Exhaustion

0.509

1.1
[0.665 1.823]
1.2 [0.56 2.67]
2.4 [1.34 4.44]
2.81 [1.67 4.72]

0.511
0.580
0.615
0.603

P Value
.71

1.97 [1.14 3.41]
2.82 [1.52 5.24]

.61
.004*
.0001*
.004*
.016
.001

1.71 [0.90 3.23]
2.34 [1.34 4.07]

.099
.003*

0.635

HF-FF, heart failure Fried Frailty index; KCCQ, Kansas City Cardiomyopathy Questionnaire.

in elderly patients with and without HF),18 sex was
not a signiﬁcant factor when assessing the impact of
frailty on outcomes.19,20 We observed that patients
with more severe heart failure (e.g., lower INTERMACS Proﬁle) had a higher prevalence of frailty
than less ill patients.
In our analysis, we also surprisingly found that
prefrail and frail patients had a higher body mass
index than nonfrail patients. This paradox highlights
a few important observations: (1) objective frailty
assessment over eyeball tests is important to permit
accurate prognostication among patients with HF
21,22
; (2) frail patients suffer from sarcopenia, and
sarcopenia can coexist in obese individuals, also
known as obese sarcopenia23,24; and (3) the combination of HF and obesity can enhance systemic
inﬂammation, muscle catabolism, and may precipitate frailty.25
Association of Frailty With Outcomes in Patients With HF

In line with previous publications, the current
study also shows worse outcomes among patients

Table 4. Univariable and Multivariable Analyses (Models) of the Primary End Point
Univariable Model

Final Multivariable Model

Characteristic

Hazard Ratio [95% CI]

P Value

Age (years)
Sex (male)
BMI (kg/m2)
INTERMACS proﬁle (IPP)
IPP 4 vs 7
IPP 5 vs 7
IPP 6 vs 7
Creatinine (mg/dL)
Albumin (g/dL)
LVEF (%)
Frailty
Prefrail vs nonfrail
Frail vs nonfrail

1.00 [0.98 1.01]
0.96 [0.58 1.61]
1.00 [0.96 1.03]

.652
.883
.810
.027

2.83 [1.24
2.51 [1.28
1.81 [0.98
1.12 [0.86
1.51 [0.84
0.97 [0.93

6.46]
4.91]
3.35]
1.44]
2.71]
1.00]

1.97 [1.13 3.41]
2.82 [1.52 5.24]

.404
.172
.057
.004
.016
.001

Hazard Ratio [95% CI]

P Value

0.98 [0.95 1.02]

.344

0.96 [0.93 0.99]

.018
<.001
.008
<.001

2.11 [1.21 3.66]
3.41 [1.79 6.52]

CI, conﬁdence interval; LVEF, left ventricular ejection fraction. Other abbreviations as in Table 1.
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found to be frail. For example, a systematic review
demonstrated that frailty increases the risk for HF
hospitalizations by 30% and all-cause mortality by
60%.20 In advanced HF, Jha et al17 demonstrated
that the prevalence of frailty confers a higher risk of
needing an left ventricular assist device or transplantation. In addition, the presence of preoperative
frailty in heart transplant recipients was associated
with inferior survival after transplant.17,26 The current study focuses not only on the assessment and
prevalence of frailty, but also uniquely demonstrated its association with the combined trajectory
outcome of durable MCS, transplant or death at 1
year. Prior HF frailty publications have not assessed
risk associated with the presence of prefrailty alone
and our ﬁndings suggest that prefrailty confers
increased risk of HF progression.
Individual Domains of the HF-Fried Frailty Index

The overall discriminatory power of the HF-Fried
Frailty index for the primary composite end point
was modest, with a Harrel’s c-statistic of 0.60, with
varying discriminatory power among the 5 frailty
domains assessed. Overall, handgrip strength and
15-foot gait time had poor predictive power, with a
c-statistic of approximately 0.5. This ﬁnding is distinct from prior publications, which have suggested
that handgrip strength among candidates for left
ventricular assist device implantation was highly predictive of outcomes after left ventricular assist
device implantation.6 We also identiﬁed a low prevalence of weight loss (approximately 1% of patients)
similar to that reported by Reeves et al, but disparate from the 38% reported by Vidan et al,29 likely
owing to the advanced age of their cohort compared with the current analysis. In fact, in the
REVIVAL population body-mass index was actually
higher with increasing degree of frailty.27,28 Assessment of weight changes in HF is challenging owing
to ﬂuctuations in volume status, where loss of muscle mass may be masked by hypervolemia, again
suggesting that weight loss may not be a critical
component of the frailty assessment in patients living with HF. 12,24,25
Perhaps most interestingly, the modest predictive
power of the HF-Fried Frailty index in this population of patients with HF was driven primarily by
questions on inactivity and exhaustion. The importance of assessing these domains has been similarly
noted in prior HF frailty studies, where they were
observed to be more predictive of one-year mortality than gait time, weight loss, or grip strength.29 It
also suggests that the KCCQ, which is extensively validated and used in HF, contains domains that can be
used to quantitatively assess exhaustion and inactivity as part of the HF frailty assessment. Further,

assessments based on the questions of inactivity and
fatigue had equivalent predictive performance to
the clinical summary and overall KCCQ scores,
underscoring their speciﬁc relevance to this HF population.
Limitations
There are limitations to this analysis that warrant mention. Despite multiple reports demonstrating the association of frailty with worse
outcomes in HF, a gold standard for frailty has
yet to be deﬁned in this population. Two components of the HF-Fried Frailty criteria previously
validated in other contexts, namely, handgrip
strength and 15-foot gait time, should be evaluated in other HF samples to reassess their performance before dismissing them as not valuable
indicators of frailty in HF. Indeed, different
thresholds have been used to qualify for weakness using handgrip strength.30 REVIVAL excluded
patients with severe chronic kidney disease and
end-stage renal disease who often meet outlined
criteria for frailty, and as such our ﬁndings cannot
be extrapolated to such a population. We also
adjusted for a modest number of covariates and
did not evaluate the impact of cognitive
impairment or depression,2,26 which may modulate frailty-associated risk.31 Three-quarters of the
REVIVAL population were men, lending to an
under-representation of women in the current
analysis; however, this proportion is in line with
studies of patients with advanced HF awaiting
transplantation or MCS.32,33 Outcomes were
assessed up until 1 year, and a longer follow-up
may inﬂuence the results.34 Finally, it could be
that the employment of another frailty tool or
measure might have detected a higher prevalence
of frailty and yielded different association with
the primary composite end point. Still, studies
have found that frailty screens and measures
have been at least moderately correlated with
one another, reﬂecting the detection of a common underlying phenotype.1
Conclusions
Understanding the best way to assess frailty
and its association with outcomes is undeniably
important to better risk stratify and care for
patients with advanced HF. We report the modest
predictive value of applying the HF-Fried Frailty
criteria to determine clinical trajectory in HF
including death, or the requirement for advanced
therapies over 1 year. Notably, assessments of
inactivity and exhaustion are readily translated to
the clinical environment and provide important
prognostic information.
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